Logo image of AVDL

AVADEL PHARMACEUTICALS (AVDL) Stock Fundamental Analysis

NASDAQ:AVDL - Nasdaq - IE00BDGMC594 - Common Stock - Currency: USD

11.08  +0.57 (+5.42%)

After market: 11.08 0 (0%)

Fundamental Rating

4

Taking everything into account, AVDL scores 4 out of 10 in our fundamental rating. AVDL was compared to 194 industry peers in the Pharmaceuticals industry. AVDL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. AVDL is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year AVDL has reported negative net income.
In the past year AVDL has reported a negative cash flow from operations.
In the past 5 years AVDL reported 4 times negative net income.
AVDL had a negative operating cash flow in each of the past 5 years.
AVDL Yearly Net Income VS EBIT VS OCF VS FCFAVDL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M

1.2 Ratios

With a decent Return On Assets value of -15.73%, AVDL is doing good in the industry, outperforming 64.43% of the companies in the same industry.
AVDL's Return On Equity of -35.66% is in line compared to the rest of the industry. AVDL outperforms 59.28% of its industry peers.
Industry RankSector Rank
ROA -15.73%
ROE -35.66%
ROIC N/A
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AVDL Yearly ROA, ROE, ROICAVDL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

AVDL has a Gross Margin of 90.06%. This is amongst the best in the industry. AVDL outperforms 93.81% of its industry peers.
In the last couple of years the Gross Margin of AVDL has grown nicely.
The Profit Margin and Operating Margin are not available for AVDL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
AVDL Yearly Profit, Operating, Gross MarginsAVDL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

6

2. Health

2.1 Basic Checks

AVDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AVDL has more shares outstanding
Compared to 5 years ago, AVDL has more shares outstanding
There is no outstanding debt for AVDL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVDL Yearly Shares OutstandingAVDL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AVDL Yearly Total Debt VS Total AssetsAVDL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of 0.83, we must say that AVDL is in the distress zone and has some risk of bankruptcy.
AVDL has a Altman-Z score (0.83) which is in line with its industry peers.
AVDL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.83
ROIC/WACCN/A
WACC7.49%
AVDL Yearly LT Debt VS Equity VS FCFAVDL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

AVDL has a Current Ratio of 2.73. This indicates that AVDL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of AVDL (2.73) is comparable to the rest of the industry.
AVDL has a Quick Ratio of 2.33. This indicates that AVDL is financially healthy and has no problem in meeting its short term obligations.
AVDL's Quick ratio of 2.33 is in line compared to the rest of the industry. AVDL outperforms 48.45% of its industry peers.
Industry RankSector Rank
Current Ratio 2.73
Quick Ratio 2.33
AVDL Yearly Current Assets VS Current LiabilitesAVDL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 85.25% over the past year.
The Revenue has grown by 252.64% in the past year. This is a very strong growth!
AVDL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.35% yearly.
EPS 1Y (TTM)85.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.33%
Revenue 1Y (TTM)252.64%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%93.21%

3.2 Future

The Earnings Per Share is expected to grow by 46.24% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 23.30% on average over the next years. This is a very strong growth
EPS Next Y144%
EPS Next 2Y87.45%
EPS Next 3Y67.28%
EPS Next 5Y46.24%
Revenue Next Year54.13%
Revenue Next 2Y41.8%
Revenue Next 3Y33.79%
Revenue Next 5Y23.31%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
AVDL Yearly Revenue VS EstimatesAVDL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
AVDL Yearly EPS VS EstimatesAVDL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVDL. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 14.08, which indicates a correct valuation of AVDL.
80.93% of the companies in the same industry are more expensive than AVDL, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.21, AVDL is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 14.08
AVDL Price Earnings VS Forward Price EarningsAVDL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVDL Per share dataAVDL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

AVDL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AVDL's earnings are expected to grow with 67.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y87.45%
EPS Next 3Y67.28%

More info and screens

0

5. Dividend

5.1 Amount

AVDL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVADEL PHARMACEUTICALS

NASDAQ:AVDL (8/1/2025, 8:21:47 PM)

After market: 11.08 0 (0%)

11.08

+0.57 (+5.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners83.33%
Inst Owner Change0.04%
Ins Owners4.92%
Ins Owner Change1.34%
Market Cap1.00B
Analysts84
Price Target17.47 (57.67%)
Short Float %14.28%
Short Ratio9.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.53%
Min EPS beat(2)-20.15%
Max EPS beat(2)31.2%
EPS beat(4)3
Avg EPS beat(4)17.39%
Min EPS beat(4)-20.15%
Max EPS beat(4)46.72%
EPS beat(8)3
Avg EPS beat(8)-12.67%
EPS beat(12)3
Avg EPS beat(12)-30.17%
EPS beat(16)5
Avg EPS beat(16)-22.11%
Revenue beat(2)1
Avg Revenue beat(2)0.15%
Min Revenue beat(2)-1.22%
Max Revenue beat(2)1.52%
Revenue beat(4)3
Avg Revenue beat(4)2.4%
Min Revenue beat(4)-1.22%
Max Revenue beat(4)8.41%
Revenue beat(8)7
Avg Revenue beat(8)23.09%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.83%
PT rev (3m)-3.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)412.91%
EPS NY rev (1m)18.05%
EPS NY rev (3m)144.78%
Revenue NQ rev (1m)0.35%
Revenue NQ rev (3m)4.83%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)4.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 14.08
P/S 5.16
P/FCF N/A
P/OCF N/A
P/B 13.55
P/tB 17.53
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)0.79
Fwd EY7.1%
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS2.15
BVpS0.82
TBVpS0.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.73%
ROE -35.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.06%
FCFM N/A
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
F-Score4
Asset Turnover1.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.73
Quick Ratio 2.33
Altman-Z 0.83
F-Score4
WACC7.49%
ROIC/WACCN/A
Cap/Depr(3y)15.99%
Cap/Depr(5y)11.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.33%
EPS Next Y144%
EPS Next 2Y87.45%
EPS Next 3Y67.28%
EPS Next 5Y46.24%
Revenue 1Y (TTM)252.64%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%93.21%
Revenue Next Year54.13%
Revenue Next 2Y41.8%
Revenue Next 3Y33.79%
Revenue Next 5Y23.31%
EBIT growth 1Y85.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year186.69%
EBIT Next 3Y90.38%
EBIT Next 5Y42.35%
FCF growth 1Y62.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.75%
OCF growth 3YN/A
OCF growth 5YN/A